Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder

被引：7

作者：

Fontenelle, LF

Mendlowicz, MV

Miguel, EC

Versiani, M

机构：

[1] IPUB UFRJ, Inst Psychiat, Anxiety & Depress Res Program, Rio De Janeiro, Brazil

[2] IPUB UFRJ, Inst Psychiat, Ethics & Forens Psychiat Res Program, Rio De Janeiro, Brazil

[3] UFF, MSM, Dept Psychiat & Mental Hlth, Niteroi, RJ, Brazil

[4] USP, Sch Med, Obsess Compuls Spectrum Disorders Clin PROTOG, Dept Psychiat, BR-09500900 Sao Paulo, Brazil

来源：

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY | 2005年 / 6卷 / 01期

关键词：

obsessive-compulsive disorder; citalopram; reboxetine;

D O I：

10.1080/15622970510029740

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

While serotonin reuptake inhibitors (SRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), as many as 40-60% of patients fail to respond to adequate trials with these drugs. In this study, we describe the case of a patient with an SRI-resistant OCD who was successfully treated with a combination of citalopram (a selective SRI) and reboxetine (a selective noradrenaline reuptake inhibitor (SNRI)). This report suggests that future studies accessing the efficacy of the SRI-SNRI combination in treatment resistant OCD are needed.

引用

页码：57 / 59

页数：3

共 22 条

[21] Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder [J].